Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biothera
Biothera Launches Clinical Trial in KRAS-Mutated Colorectal Cancer Patients
June 30th, 2009
Biothera has initiated a Phase II clinical trial in stage IV KRAS-mutated colorectal cancer patients with its investigational drug Imprime PGG® in combination with Erbitux® (cetuximab), the company announced. Published research demonstrates that colorectal cancers with mutated KRAS genes do not respond to anti-EGFR monoclonal antibodies such as Erbitux®. However, researchers believe that Imprime PGG® uses the body's own immune system by engaging a type of white blood cell called the neutrophil to fight cancer cells that are coated with antibodies like Erbitux. Such a strategy might be effective against tumors regardless of whether KRAS is mutated or not. Preclinical...
Source: Cancer Weekly (2009-06-30)
|
